Empower Pharmacy sold untested GLP-1 weight-loss drugs as proven and personalized, a new class action claims.

On Oct. 30, 2026, Nicholas Forcier and Tameka Watson filed a class action lawsuit against Empower Pharmacy in the U.S. District Court for the District of New Jersey.

The lawsuit alleges Empower falsely marketed its compounded semaglutide and tirzepatide as clinically proven, personalized and safe.

Empower's compounded drugs

Empower, which calls itself the nation's largest compounding pharmacy, makes its own versions of the active ingredients in Ozempic, Wegovy, Mounjaro and Zepbound. Its products includes injections that mix the drugs with B vitamins and tablets that dissolve in the mouth.

The class action claims compounded drugs lack Food and Drug Administration approval so it does not review their safety or effectiveness before patients take them.

The allegations

The plaintiffs claim Empower promoted its drugs with results from trials of the FDA-approved versions even though its own products never went through clinical trials. It also allegedly promoted a tirzepatide and vitamin B injection with a trial of tirzepatide alone, according to the proposed class action.

The lawsuit also contends Empower calls its products personalized formulations yet are standard formulas sold in fixed doses. In 2023, the company reportedly said it filled 15,000 prescriptions, according to the complaint. In September 2026, the FDA warned Empower it was compounding copies of approved GLP-1 injections "regularly and in inordinate amounts."

The filing challenges Empower's claim that it meets strict FDA and state standards, citing:


  • FDA warning letters in 2017, 2021, 2025 and 2026

  • Inspection findings of bacterial contamination, unsterile conditions and harmful bacteria in a New Jersey plant's water systems

  • Discipline from pharmacy boards in seven states and at least three drug recalls

The plainitifs claims Empower's website convinced them its products were safe and met FDA rules. They say they would have bought the drugs had they known the truth.

The legal claims

The lawsuit brings six claims:


  • New Jersey Consumer Fraud Act, which bars deceptive sales practices

  • New York General Business Law Sections 349 and 350, which are two claims covering deceptive practices and false advertising

  • Illinois Consumer Fraud and Deceptive Business Practices Act, which prohibts unfair and deceptive practices

  • Breach of express warranty, which applies when a product fails to match the seller's promises

  • Unjust enrichment, which bans a company from keeping money it gained unfairly

The New York and Illinois claims cover only buyers in those states. The plaintiffs seek full refunds, damages, punitive damages and Empower's profits from the sales plus a court order requiring corrective ads.

What the lawsuit means for compounded GLP-1 buyers

The proposed class covers anyone in the United States who bought or received compounded semaglutide or tirzepatide made by Empower.

As of this writing, there is no settlement, no claims process and no money available.